Engineered t cells take aim at Hard-to-Treat leukemia

This early-stage study tests a new approach for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to standard treatment. Researchers take a patient's own T cells, modify them in the lab to recognize and attack leukemia cells, and infuse them back after chemotherapy. The main goal is to check safety and find the right dose, while also seeing if the treatment can reduce or control the leukemia.